Neoprobe Corporation develops and commercializes biomedical products. The company produces devices to meet the intra-operative, diagnostic and therapeutic treatment needs of patients and physicians. It focuses on the use of gamma-detection systems in combination with radiopharmaceutical agents to improve cancer surgery outcomes. Through Cardiosonix, Neoprobe has developed the Quantix line of blood flow measurement products for a variety of clinical needs, including real-time monitoring, intra-operative quantification, non-invasive diagnostics and blood flow evaluation. The company s Cira Biosciences unit explores activated cellular technology for the potential treatment of viral and autoimmune diseases. Neoprobe Corporation is headquartered in Dublin, Ohio.